The use of circulating, cell-free DNA (cfDNA) is rapidly evolving in the clinical landscape and is one of the fastest-growing areas in recent years. It offers tremendous clinical potential as a screening method for tumor, cancer, fetal DNA studies, disease progression, treatment response, and more. Circulating DNA extraction is often challenging as they are found in low quantities, and accurate methods are needed to isolate the less abundant cfDNA with higher sensitivity and specificity. Rapid, reliable, and high throughput methodologies are needed for widespread adoption and implementation of cfDNA-based diagnostics in clinical care.
Join Omega Bio-tek’s Dr. Kiranmai Durvasula and Hamilton’s Dr. Kristina Klette as we explore the automation of Omega’s Mag-Bind® cfDNA Kit, (M3298) on the Hamilton Microlab STAR platform as well as look at other possibilities, including quantification of cfDNA, circulating tumor DNA (ctDNA) vs. cfDNA and ways to enrich ctDNA.